We are live on ! Find out more
RYTM icon

Rhythm Pharmaceuticals
RYTM

84 hedge funds and large institutions have $688M invested in Rhythm Pharmaceuticals in 2019 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 39 increasing their positions, 15 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

160% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 15

1.16% more ownership

Funds ownership: 89.65% → 90.81% (+1.2%)

7% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 14

3% less funds holding

Funds holding: 87 → 84 (-3)

19% less capital invested

Capital invested by funds: $846M → $688M (-$158M)

50% less funds holding in top 10

Funds holding in top 10: 6 → 3 (-3)

Holders
84
Holders Change
-3
Holders Change %
-3.45%
% of All Funds
1.82%
Holding in Top 10
3
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-50%
% of All Funds
0.07%
New
13
Increased
39
Reduced
15
Closed
14
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$9.6M
2
DM
Deerfield Management
New York
+$8.41M
3
UONDDL
University of Notre Dame du Lac
Indiana
+$3.5M
4
State Street
State Street
Massachusetts
+$3.33M
5
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$2.94M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$9.89M
2
PA
Perceptive Advisors
New York
-$6.06M
3
TCM
TimesSquare Capital Management
New York
-$4.64M
4
EC
EcoR1 Capital
California
-$4.49M
5
TOPU
Trustees of Princeton University
New Jersey
-$1.31M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$2.82M +$478K +18,917 +17%
JP Morgan Chase
27
JP Morgan Chase
New York
$2.75M +$77.2K +3,057 +2%
EU
28
Emory University
Georgia
$1.9M +$172K +6,810 +9%
Bank of New York Mellon
29
Bank of New York Mellon
New York
$1.89M +$417K +16,507 +24%
N
30
Nuveen
North Carolina
$1.7M +$1.95M +77,185 New
AA
31
ALPS Advisors
Colorado
$1.59M -$279K -11,045 -13%
RHJA
32
Rice Hall James & Associates
California
$1.39M +$1.01M +40,015 +172%
Goldman Sachs
33
Goldman Sachs
New York
$1.23M +$224K +8,878 +19%
HP
34
Harbourvest Partners
Massachusetts
$1.1M – – –
FI
35
Fosun International
China
$883K +$278K +11,000 +37%
California State Teachers Retirement System (CalSTRS)
36
California State Teachers Retirement System (CalSTRS)
California
$778K +$305K +12,066 +52%
Swiss National Bank
37
Swiss National Bank
Switzerland
$774K +$98.5K +3,900 +12%
HLA
38
Hamilton Lane Advisors
Pennsylvania
$764K – – –
ClearBridge Investments
39
ClearBridge Investments
New York
$677K – – –
PPA
40
Parametric Portfolio Associates
Washington
$643K +$146K +5,788 +25%
Bank of America
41
Bank of America
North Carolina
$586K +$174K +6,871 +35%
RhumbLine Advisers
42
RhumbLine Advisers
Massachusetts
$574K +$164K +6,490 +33%
DekaBank Deutsche Girozentrale
43
DekaBank Deutsche Girozentrale
Germany
$564K +$657K +26,000 New
Adage Capital Partners
44
Adage Capital Partners
Massachusetts
$550K – – –
TCM
45
Tekla Capital Management
Massachusetts
$548K – – –
Citigroup
46
Citigroup
New York
$547K +$544K +21,550 +654%
New York State Common Retirement Fund
47
New York State Common Retirement Fund
New York
$517K +$162K +6,400 +37%
TD Asset Management
48
TD Asset Management
Ontario, Canada
$496K +$98.5K +3,900 +21%
SIM
49
Spark Investment Management
New York
$473K -$434K -17,185 -44%
State of Wisconsin Investment Board
50
State of Wisconsin Investment Board
Wisconsin
$464K +$12.6K +500 +2%
1
2
3 4

RYTM Hedge Fund Activity: Q2 2019 in Review

84 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Rhythm Pharmaceuticals (RYTM) for Q2 2019, worth a combined $688M — down 19% from $846M a quarter earlier.

Sellers outnumbered buyers: 14 funds closed out of RYTM and 13 opened new positions — a net loss of 1 holder — while 15 trimmed existing stakes and 39 added.

The largest buyer was BlackRock, adding an estimated $9.6M. The largest seller was Fidelity Investments, cutting an estimated $9.89M.

  • 84 institutional investors held Rhythm Pharmaceuticals (RYTM) as of Q2 2019, down from 87 in Q1 2019.
  • Funds reported $688M of Rhythm Pharmaceuticals stock for Q2 2019, down 19% quarter-over-quarter.
  • 13 funds opened new Rhythm Pharmaceuticals positions in Q2 2019 and 14 closed out, a net change of -1 holder.
  • The largest Rhythm Pharmaceuticals buyer in Q2 2019 was BlackRock, an estimated $9.6M added.
  • The largest Rhythm Pharmaceuticals seller in Q2 2019 was Fidelity Investments, an estimated $9.89M sold.

Based on aggregated 13F filings for Q2 2019.